Abstract: The present disclosure provides inhibitors of Janus Kinase 2 (JAK2) which may be used in the treatment of medical disorders such as cancer.

Abstract: The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.

Abstract: The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.

Abstract: The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.

Abstract: A wall panel for a quick assemble wall system may include a first upright post and a second upright post. The wall panel may also include a lower stretcher for connecting the first upright post to the second upright post and an upper stretcher for connecting the first upright post to the second upright post. The wall panel may include at least one frame for placement within the first vertical post, the second vertical post, the lower stretcher, and the upper stretcher. The wall panel may include a first retractable latch located on the at least one frame, the first retractable latch adapted to engage at least one of the first upright post, second upright post, lower stretcher, or upper stretcher. A frame for a quick assemble wall system and a method of assembling a quick assemble wall system are also described.

Abstract: A wall panel includes a first upright post, a second upright post, an upper stretcher connecting the first upright post to the second upright post, a lower stretcher connecting the first upright post to the second upright post, and a frame having an extrusion profile, wherein the extrusion profile is configured to couple the frame to the wall panel frame. A wall panel assembly includes a plurality of the wall panels.

Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

Abstract: The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.

Abstract: A catheter insertion device (10) includes a housing (12) with a base (14), a catheter (28), an introducer needle (30) and an actuator (26) mounted within the housing. The catheter (28) and needle (30) are coupled to the actuator (26) and movable between a first position where the catheter and needle are retracted within the housing and a second position where the catheter (28) and needle (30) extend from the housing, and where the needle retracts into the actuator when the catheter and needle reach the second position. A spring (90) is provided in the housing (12) or the actuator (26) where the spring (90) is released after deployment of the device to retract the needle (20) with respect to the catheter (28).

Abstract: A catheter insertion device (10) includes a housing (12) with a base (14), a catheter (28), an introducer needle (30) and an actuator (26) mounted within the housing. The catheter (28) and needle (30) are coupled to the actuator (26) and movable between a first position where the catheter and needle are retracted within the housing and a second position where the catheter (28) and needle (30) extend from the housing, and where the needle retracts into the actuator when the catheter and needle reach the second position. A spring (90) is provided in the housing (12) or the actuator (26) where the spring (90) is released after deployment of the device to retract the needle (20) with respect to the catheter (28).

Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I, II, and II.

Abstract: A wall panel for a quick assemble wall system may include a first upright post and a second upright post. The wall panel may also include a lower stretcher for connecting the first upright post to the second upright post and an upper stretcher for connecting the first upright post to the second upright post. The wall panel may include at least one frame for placement within the first vertical post, the second vertical post, the lower stretcher, and the upper stretcher. The wall panel may include a first retractable latch located on the at least one frame, the first retractable latch adapted to engage at least one of the first upright post, second upright post, lower stretcher, or upper stretcher. A frame for a quick assemble wall system and a method of assembling a quick assemble wall system are also described.

Abstract: A wall panel for a quick assemble wall system may include a first upright post and a second upright post. The wall panel may also include a lower stretcher for connecting the first upright post to the second upright post and an upper stretcher for connecting the first upright post to the second upright post. The wall panel may include at least one frame for placement within the first vertical post, the second vertical post, the lower stretcher, and the upper stretcher. The wall panel may include a first retractable latch located on the at least one frame, the first retractable latch adapted to engage at least one of the first upright post, second upright post, lower stretcher, or upper stretcher. A frame for a quick assemble wall system and a method of assembling a quick assemble wall system are also described.

Abstract: The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.

Abstract: The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.

Abstract: An insulin infusion device (1A) is disclosed. The device includes a body (3A), cannula (70) housed in the body (1A), a cannula insertion device (10, 20, 23) and a cannula retraction device (20, 23, 30). When the cannula insertion device is activated, the cannula (70) extends at least partly out of the body (1A) and into an infusion site and when the cannula retraction device is activated after the cannula insertion device has been activated, the cannula (70) retracts into the body (1A).

Abstract: A table having a table top, a bracket secured to the table top, a latching device coupled to the bracket, the latching device having a retaining wedge coupled to a draw latch via a cam device, and a table leg. The draw latch is configured to move the retaining wedge between a first position securing the table leg to the bracket and a second position unsecuring the table leg from the bracket.

Abstract: A table having a table top, a bracket secured to the table top, a latching device coupled to the bracket, the latching device having a retaining wedge coupled to a draw latch via a cam device, and a table leg. The draw latch is configured to move the retaining wedge between a first position securing the table leg to the bracket and a second position unsecuring the table leg from the bracket.

Abstract: A catheter insertion device (10) includes a housing (12) with a base (14), a catheter (28), an introducer needle (30) and an actuator (26) mounted within the housing. The catheter (28) and needle (30) are coupled to the actuator (26) and movable between a first position where the catheter and needle are retracted within the housing and a second position where the catheter (28) and needle (30) extend from the housing, and where the needle retracts into the actuator when the catheter and needle reach the second position. A spring (90) is provided in the housing (12) or the actuator (26) where the spring (90) is released after deployment of the device to retract the needle (20) with respect to the catheter (28).

Abstract: The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.